about
Degradation of the disease-associated prion protein by a serine protease from lichensCalcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survivalUV-light exposed prion protein fails to form amyloid fibrilsThe efficacy of tetracyclines in peripheral and intracerebral prion infection.Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity.Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agentsStructure-based drug design identifies polythiophenes as antiprion compounds.Screening and identification of compounds with antiviral activity against hepatitis B virus using a safe compound library and novel real-time immune-absorbance PCR-based high throughput system.The intricate mechanisms of neurodegeneration in prion diseases.Inherited prion disease A117V is not simply a proteinopathy but produces prions transmissible to transgenic mice expressing homologous prion protein.Protein folding activity of the ribosome (PFAR) -- a target for antiprion compoundsPrion Protein-Antibody Complexes Characterized by Chromatography-Coupled Small-Angle X-Ray Scattering.Prion strain- and species-dependent effects of antiprion molecules in primary neuronal culturesCurrent and future molecular diagnostics for prion diseases.The prion strain phenomenon: molecular basis and unprecedented features.Discovery and Preliminary SAR of Arylpiperazines as Novel, Brainpenetrant Antiprion Compounds.Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice.Anti-LRP/LR antibody W3 hampers peripheral PrPSc propagation in scrapie infected mice.Human tonsil-derived follicular dendritic-like cells are refractory to human prion infection in vitro and traffic disease-associated prion protein to lysosomes.
P2860
Q21135451-3BD6E5F6-2879-44A8-A13D-383693EE1F59Q27313215-EAA8B058-908E-4D3C-9E6C-7CB633B0541BQ28473110-744E1FC9-341E-4D52-82D4-729F58DFEBF0Q30496598-5BA58056-7391-47B8-9BD9-D6AA879D511BQ33560026-E0F320E1-99A0-4D83-AF90-9437D9C37D86Q34036311-8DE0143D-5FD8-4154-851B-7C5668089D63Q34488418-71D35A77-4068-4A22-A012-6D574ADFA0E4Q34588956-DE023DCF-6C2A-4EA3-A86C-08118852A8AEQ34664576-7E72DDA9-C6EA-4577-AE02-12DA5226A822Q35004466-46E3FD03-604F-4770-A54C-8AA1658191DAQ35363080-04BB6981-EFB0-4ABC-82AE-1AE7CD507799Q35989584-71A1FED5-0AE0-43E5-9CBA-C809DFB5A870Q36315218-D57A4F75-B293-4720-9E9B-722B2CBBF6E4Q36528891-7F16698B-1F3A-44B8-8C23-96F1188ED95BQ36718712-A45A2C01-8E7B-47EB-A3C5-F4510281FAB2Q36991608-EB55C162-FB55-4708-B993-66AABBB0002AQ37080697-E28ABD65-BA1C-4167-AE35-C593E0712533Q37080701-F68A1647-43CA-483E-8969-D1FEF64FD3BCQ37415409-65F050AA-B012-47E3-8AD9-1319598387E2
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Approaches to therapy of prion diseases.
@ast
Approaches to therapy of prion diseases.
@en
type
label
Approaches to therapy of prion diseases.
@ast
Approaches to therapy of prion diseases.
@en
prefLabel
Approaches to therapy of prion diseases.
@ast
Approaches to therapy of prion diseases.
@en
P1476
Approaches to therapy of prion diseases.
@en
P2093
Charles Weissmann
P304
P356
10.1146/ANNUREV.MED.56.062404.172936
P577
2005-01-01T00:00:00Z